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T 
HE quinidine-like action of the antihista- 
mines was first observed by Dews and 
Graham’ and confirmed by Dutta.2 Dutta3 
then observed that antazoline (Antistine,@ 
Ciba), an antihistamine introduced by Meier 
and Bucher,4 appeared more active than quini- 
dine. Clinical interest was stimulated by the 
Angelakos and Hegnauersvs studies in dogs 
showing that antazoline, as well as other anti- 
histamines, and quinidine afforded high pro- 
tection against ventricular fibrillation in hypo- 
thermia. The over-all survival was limited by 
the development of acute heart failure in many 
treated animals that escaped ventricular fibrilla- 
tion, but this could be overcome by inotropic 
agents. Kline and Dreifus and their associates7+s 
observed that in dogs intravenous antazoline 
caused a transient reduction in cardiac output 
and a rise in peripheral resistance, with the 
blood pressure and heart rate remaining con- 
stant. In clinical trials among 112 patients 
with 141 disturbances of rhythm they found 
antazoline to be an effective, well tolerated 
antiarrhythmic agent which was useful in the 
therapy of ectopic beats of atrial, nodal or 
ventricular origin. It was ineffective in the 
conversion of atria1 flutter and atria1 fibrilla- 
tion. 
Thus, animal studies and preliminary clinical 
trials provided evidence that antazoline has 
antiarrhythmic actions in addition to its known 
antihistamine effects. Because the preliminary 
studies were encouraging, it was felt that further 
trials in many different kinds of disturbances of 
cardiac rhythm were indicated. 
MATERIAL AND METHODS 
The present series consisted of 115 patients with 
137 cardiac arrhythmias selected from the medical 
and surgical wards of the University of Michigan 
Hospital, the Heart Station and the Ann Arbor Veter- 
ans Hospital. With the exception of patients with 
atria1 fibrillation and atria1 flutter, some of whom 
were not included in the study, the selection repre- 
sented no known bias toward any one group. No 
other conditions were so handled, and the number of 
patients with other arrhythmias approximately repre- 
sented their incidence during the period of the study. 
To avoid eliminating those patients who might not 
respond or who might have early side effects, no 
patients were dropped from the study because of poor 
follow-up or inadequate data. 
More than one half of the patients were over 59 
years of age. There was no associated heart disease 
in 25 patients; 45 had coronary artery disease; 10 
had rheumatic heart disease; and the remainder had 
miscellaneous kinds of heart disease. There were 13 
deaths, and 9 postmortem examinations were made. 
None of the deaths could be attributed directly to 
antazoline, but all occurred in patients in the ter- 
minal phase of their disease. 
All patients were evaluated by one or more of the 
authors during periods of hospitalization and in 
the follow-up visits to the Heart Station. There 
the arrhythmia was investigated by reviewing the 
patient’s report card with him to determine the dates, 
duration and frequency of paroxysmal arrhythmias 
and by taking a three-minute count of the number of 
premature beats and/or monitoring their frequency 
with a recording cardiotachometer for from 15 
minutes to 24 hours. 
Where circumstances permitted, a control period 
and/or trial on another antiarrhythmic agent for an 
equal or greater period was used in lieu of placebo 
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TABLF. I 
Effectiveness of Antazoline in Conversion of Cardiac 
Arrhythmias 
Disturbance of No. of r---Effect-, 
Rhythm Gases Good None 
Paroxysmal atria1 tachycardia 2 1 1 
Atria1 flutter 4 1 3 
Atria1 fibrillation 7 1 (1 
Ventricular tachycardia 5 4 1 
Ventricular fibrillation (see 
text) 2 2 0 
control. A control period on a placebo, using the 
single-blind technic, was satisfactorily accomplished 
for long periods of time in only 5 patients. Recurrence 
of paroxysms of supraventricular arrhythmia which 
were unpleasant to the patient and paroxysmal ven- 
tricular tachycardia or other threats to the patient’s 
life, plus inadvertent knowledge or suspicion by the 
patient that he was receiving a placebo, were the 
main reasons for failure of the planned placebo control 
period. In many other instances such a placebo con- 
trol period could not be obtained or was not needed, 
as,: for example, in the conversion of cardiac ar- 
rhythmias. 
Comparison of antazoline with other antiar- 
rhythmic drugs was accomplished by monitoring 13 
patients with the recording cardiotachometer for 24 
hours on no antiarrhythmic drug and for 24 hours 
each on at least two other drugs, such as quinidine 
sulfate, procaine amide, Alderlin@ (Ayerst), atropine, 
digitalis and reserpine, and by counting the fre- 
quency of premature beats in the 24 hour period. 
This method is more precise than other methods of 
counting premature beats, but because it became 
available late in the study, and few patients were 
studied in this way, the results are not tabulated 
separately. 
RESULTS 
Abolition of cardiac arrhythmias, prevention 
of paroxysms of rapid heart action and the pre- 
vention of premature beats are separate aspects 
of this study and will be considered separately. 
ABOLITION OF ABNORMAL RHYTHM 
Attempts were made to terminate abnormal 
cardiac rhythm in 19 patients, and the results 
are listed in Table I. 
Atria1 Flutter and Fibrillation: Conversion of 
atria1 flutter or atria1 fibrillation was attempted 
11 times in 10 patients, both conditions occur- 
ring in 1 patient at different times. There was 
one successful conversion of each. Of the 4 
patients in whom unsuccessful attempts were 
made to terminate atria1 flutter, 3 received only 
oral medication with multiple dosage schedules 
of 100 or 200 mg. every one or two hours for 
six doses. The one success occurred in a 70 
year old woman with thyrotoxicosis given 350 
T”hg. 
intravenously, with prompt conversion. 
e patient died one week later, possibly due 
to an overdose of chloral hydrate and other 
causes. All patients treated had slowing of the 
atria1 rate, whether or not conversion took place. 
FIG. 1. Sequential electrocardiographic tracings of lead Vr showing the termination of ven- 
tricular tachycardia with 450 mg. of antazoline intravenously. 
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TABLE II 
Effectiveness of Antazoline in the Prevention of Paroxysmal Cardiac Arrhythmias* 
Disturbance of Rhythm 
NO. 
Patients Good 
Effect - Insufficient 














Per cent of total 
28 9 3 6 6 4 
41 12 6 5 12 6 
4 . . 1 1 . . . 2 
3 1 . . . . 2 . . . 
10 2 2 2 3 1 
2 . . . . 1 . . . 1 
9 1 1 1 2 4 
6 . . . . . 1 3 2 
8 . . . . 2 4 2 
6 . . 1 1 2 2 
117 25 14 20 34 24 
100 21.4 12.0 17.1 29.0 20.5 
* In the prevention of paroxysmal arrhythmias or premature beats the following limits apply to the evaluation: 
E&tiue: Rhythm studied ceases altogether or with less than 5 per cent residual breakthrough. Moderate: Suppression 
of rhythm studied reaches 70 per cent, with 30 per cent or less residual breakthrough in number of attacks or numbers 
of premature beats. Slight: Data are not always conclusive, but the evidence shows some suppression of the rhythm 
studied. 
t No ECG obtained during attack. 
In 7 patients in whom attempts to abolish 
atria1 fibrillation were made, only 6 received 
an adequate dosage. The seventh patient, 
treated early in the study, received only 200 
mg. four times a day. Of the remaining 6, 1 
received 400 mg. of antazoline intravenously 
in 22 minutes, and in addition to the oral sched- 
ules listed here, 1 received 1,500 mg. intrave- 
nously in 1 hour and 55 minutes, with only mild 
symptoms and without converting his rhythm. 
The one success was achieved in a 43 year old 
man who developed atria1 fibrillation during 
cardiac catheterization, which persisted for 
five days prior to the attempt at conversion, 
during which time he was fully digitalized. 
The effective dose was 100 mg. each hour for 
four doses. Normal sinus rhythm persisted 
after the conversion. The oral schedules used 
in the unsuccessful attempts were 100 or 200 
mg. every one or two hours. In 1 case the 
schedule was 300 mg. every two hours for six 
doses. 
Ventricular Tuchycardz’u: By far the best re- 
sults were obtained in the abolition of ventricular 
arrhythmias. Out of 5 patients with ventricular 
tachycardia, 4 were converted to normal sinus 
rhythm, by using 400 to 600 mg. of antazoline 
diluted and given intravenously over a 30 
minute period. The one failure was in an un- 
conscious patient with fresh myocardial infarc- 
tion and ventricular tachycardia who subse- 
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quently died. Prior to death the QRS com- 
plexes became wide and were of sine wave 
configuration, resembling potassium intoxica- 
tion. Figure 1 illustrates the sequence of a 
successful conversion of proved ventricular 
tachycardia. 
Ventricular Fibrillation: Two patients experi- 
enced cardiac arrest due to ventricular fibrilla- 
tion, and it is felt that antazoline was effective 
in preventing a recurrence of this rhythm after 
electrical countershock conversion of the ventric- 
ular fibrillation. In one of these patients ven- 
tricular tachycardia developed after ventricular 
fibrillation was converted with electric counter- 
shock. The ventricular tachycardia was then 
treated by giving 200 mg. of procaine amide 
intravenously. Ventricular fibrillation recurred, 
and after a considerable period of cardiac mas- 
sage, 100 mg. of antazoline was given intra- 
venously, and the rhythm returned to a normal 
sinus mechanism within 10 minutes. Normal 
rhythm was maintained for two weeks, at the 
end of which the patient died of pulmonary 
complications. 
The second patient had a fresh posterolateral 
myocardial infarction with ventricular fibrilla- 
tion, which recurred after each of two attempts 
of electrical defibrillation. Antazoline, 600 mg., 
was given intravenously, and the thiid electrical 
conversion was successful in that normal sinus 
rhythm persisted. It is obvious that antazoline 
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was usefui only in conjunction with alternating 
current defibrillation, but both of these encour- 
aging outcomes would seem to justify further 
study of antazoline in ventricular fibrillation. 
PREVENTION OF PAROXYSMAL ARRHYTHMIAS 
Evaluation of the ability of antazoline or an) 
antiarrhythmic agent to prevent attacks of 
rapid heart action is most difficult, for the 
groups studied were not homogeneous in any 
sense except for the rhythm disturbance itself. 
The frequency of attacks, presence of heart 
disease, age group and presence of associated 
anxiety are all factors that cannot be eliminated 
by group study of the type described here. 
Thus, each patient had to serve as his own con- 
trol. The rhythm disturbances, with few 
exceptions, were so intermittent that they could 
not be documented, and so reliance had to be 
placed on a report card system. Table II lists 
the results of the use of antazoline in this group 
of patients. 
Prevention of Premature Beats: Antazoline in 
an oral dose of 100 or 200 mg. four times a day 
was effective or moderately effective in 12 of 24 
patients with proved frequent atria1 premature 
beats in which study was adequate and in 18 
of 35 patients with ventricular premature beats. 
Figure 2. illustrates how evaluation was made 
in a patient with many premature beats. The 
patient, a 58 year old white man, had a two 
year history of rapid heart action every two 
months. He was admitted to the hospital 
following such an attack, during which he lost 
consciousness while driving and crashed into a 
tree. The electrocardiogram revealed ventricu- 
lar premature beats, and the 24 hour contin- 
uously monitored heart rate revealed an average 
of 126 ventricular premature beats for each 16 
minute period during the 24 hours. This figure 
compares with the 24 hour average of 37 every 
16 minutes during antazoline therapy. This 
represented a 71 per cent reduction, and there- 
fore the drug was considered moderately effec- 
tive, with a 29 per cent residual breakthrough. 
Although moderately effective, it was not as 
CONTROL 
QUINAGLUTE GRS X Q I2 HOURS 
L. H. 022803 16 MINUTE RECORDINGS 
FIG. 2. Digital cardiotachometer recordings made during four successive 24 hour periods of drug therapy. The 
records are read from right to left and are measurements made from the R-R interval of the electrocardiogram: Heart 
rate = 60/R-R(sec. ). Thus, each premature beat appears as a vertical line, the top of which indicates the shorter R-R 
interval (faster rate) followed by a compensatory pause (slower rate). These 16 minute samples were selected from 24 
hour recordings, so that the number of premature beats shown corresponds with the 24 hour average for the particular 
drug studied. The lower strip shows the onset of action of procaine amide one hour after the drug was taken. The 
suppressive effect shown to the left lasted one hour. The other drugs studied showed more uniform action. 
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ANTAZOLINE 200 MGM 0.1. D. 10/31/62 
r I i --/ I 
FIG. 3. Paroxysmal ventricular tachycardia and ventricular premature beats in a 60 year old man. These 
two selections from 24 hour recordings show the superiority of antazoline compared with procaine amide in 
suppressing ventricular premature beats. 
effective as quinidine in the prevention of pre- 
mature beats in this patient. Since the follow- 
up period was only one month, it was not felt 
proper to evaluate the effectiveness in the un- 
diagnosed rapid heart action, although the pa- 
tient was free of attacks during this period. 
Figure 2 was prepared by selecting samples 
from the 24-hour recordings that corresponded 
with the number of premature beats as shown 
by the 24 hour average in this patient. 
The next 5 patients illustrate clinical situa- 
tions where therapy of premature beats ap- 
peared justified to prevent the occurrence of a 
more serious arrhythmia. 
Figure 3 is a cardiotachometer record taken 
on a 60 year old man with paroxysmal ventricu- 
lar tachycardia proved by electrocardiograms. 
In addition, he had frequent ventricular prema- 
ture beats during the period of ineffective 
treatment with procaine amide. Antazoline 
was effective in suppressing both disturbances of 
rhythm. 
Figure 4 is a record from a 49 year old woman 
who had fresh myocardial infarction on the 
day the tracings were taken. It shows two 
strips of electrocardiograms taken several hours 
apart and is representative of the clinical situa- 
tion as observed over a two month period. 
Bigeminy, seen in the first tracing, was abolished 
by antazoline but recurred two months later 
when the drug was discontinued and ceased 
again when the drug was restarted. It has 
not recurred in a further six month period of 
antazoline therapy. 
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Figures 5 to 7 illustrate the value of continu- 
ously monitoring the heart rate of patients to 
evaluate both the dose (Fig. 5) and choice of 
drug (Fig. 6 and 7) needed to suppress prema- 
ture beats in patients with coronary artery 
disease. 
Prevention of Paroxysmal Tachycardia: There 
j + / 
AFTER 200mom ANTAZOLINE 
FIG. 4. Bigeminal rhythm following fresh posterior myo- 
cardial infarction was effectively controlled with anta- 
zoline. 
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dNTAZO\INE 200 MGM Q 6,yR. li” 10/24/62 I 
QUINAGLUTE OR. X Q12 HR. 10/2S/62 -__- HIS, 
S.W. A91 16 YIN. RECORDINGS 
FIG. 5. Acute myocardial infarction and frequent atria1 premature beats in 39 year old woman. Repre- 
sentative recordings from three 24 hour periods of drug therapy show the frequency of premature beats 
for two dose ranges of antazoline compared with a long-acting quinidine preparation. 





1 _- / 
ANTAZOLINE 200 MGM 0 6 HR. (28 prern-b~$_beat? ip this 24 hr. period) I l/28/62 
/ / I 
I ~!_~__d_ ._ I_ I 
A.L. Al01 ’ 16 MIA. RECki@% 
FIG. 6. Fresh myocardial infarction and atria1 bigeminy in a 65 year old man. Antazoline in the dose shown 
was effective in suppressing the atria1 premature beats; procaine amide was ineffective. 
were 10 patients with paroxysmal atria1 tachy- 
cardia. Of 2 in this group who had recurrent 
atria1 tachycardia due to digitalis intoxication, 
antazoline was effective in 1; the second patient 
was given other drugs such as potassium chloride 
making it quite impossible to evaluate any effects 
of antazoline other than the side reactions. 
The remaining 8 patients were followed up from 
4 to 12 months (average, 7.7 months) to deter- 
mine the frequency of recurrent attacks of atria1 
tachycardia, and antazoline was found at least 
moderately effective in 3. 
Antazoline .was used to prevent paroxysmal 
atria1 jutter in 6 patients on follow-up for an 
average of 8.9 months and in paroxysmal atria1 
fibrillation in 8 patients followed for an average 
of 7.9 months. One of these patients was 
followed for 21.5 months and had 18 attacks of 
atria1 fibrillation in 5l/2 months under no therapy, 
5 attacks in 3 months of placebo therapy, and 
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FIG. 7. Tracings from a 69 year old woman with angina pectoris and almost constant atrial premature beats 
during the 24 hour control period (upper trace). Alderlin, a beta adrenergic blocking agent, was slightly 
effective (middle trace). but antazoline was classed as the most effective. The dose, time of administration and ,, 
the time the record was taken are shown. 
14 attacks in 13 months while receiving antazo- 
line in 100 and 200 mg. doses four times a day. 
This was felt to be a significant reduction in 
number of attacks but was interpreted as only 
slightly effective. The effects of the drug in 1 
of the patients with paroxysmal atria1 fibrilla- 
tion could not be evaluated because he had 
received only the placebo before being lost to 
follow-up. The results in another patient 
could not be evaluated because the paroxysmal 
atria1 fibrillation simply disappeared and failed 
to return after the drug was stopped. In 4 
patients on follow-up for 3, 7, 14 and 17 months 
respectively, the drug was ineffective. One 
of these patients had an adequate quinidine 
trial, which was also ineffective. 
Six patients with paroxysmal ventricular tachy- 
cardia were studied. In 1 of the patients in 
whom the drug was considered ineffective, 
ventricular premature beats could be suppressed 
by antazoline. In the 1 case in which the drug 
was moderately effective there was no known 
heart disease, but the patient experienced re- 
peated attacks of syncope due to ventricular 
tachycardia over a 27 month period of observa- 
tion. These attacks could not be prevented by 
quinidine sulfate, quinidine gluconate in a 
long-acting preparation or by procaine amide. 
Seven attacks of ventricular tachycardia were 
observed in one month. Antazoline in a dose 
of 100 mg. 4 times a day was also ineffective, 
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but when the dose was increased to 200 mg. 
four times a day, the number of attacks was 
reduced to less than one a month (8 total in 10 
months of observation on antazoline). 
SIDE EFFECTS AND TOXIC REACTIONS 
Table III lists the frequency of side actions 
in 108 of the patients. Side effects could not 
TABLE III 
Side Effects and Toxic Reactions in 108 Patients 
No. of ‘% of 
Patients Total 
Total patients having side effects 60 55.6 
Transient or minimal 39 36.1 
Severe 21* 19.4* 
Side effects 
Anorexia only 5 4.6 
Nausea and/or vomiting 37 34.3 
Drowsiness and/or fatigue 18 16.7 
Diarrhea 5 4.6 
Epigastric distress 7 6.5 
Dizziness and lightheadedness 4 3.7 
Weakness 6 5.6 
Other t 15 13.9 
* Includes 5 patients receiving large doses for rhythm 
conversion. 
t Headache, chills, fever, muscle spasm, clouded sen- 
sorium, disorientation, confusion, full-feeling in head, 
tremor, scaling dermatitis of hands and scalp, abdomi- 
nal cramps, eosinophilia, aberration of QRS complex, 
flushed sensation and hiccoughs. 
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be evaluated in the remaining 7 patients bc- 
cause of poor reporting. Xfzusca or vamiting, or 
both, constituted the chief side effect, and this 
could be prevented in most patients by taking 
the drug with meals or with an antacid prepara- 
tion. The second most frequent side effect 
was drowsiness, but it was not severe enough 
to necessitate stopping the drug. Few severe 
side reactions were encountered, but these are 
worth reporting. They were as follows: 
Chills and Fever: A 65 year old physician 
was given 100 mg. of antazoline four times a 
day as prophylaxis against frequent attacks of 
rapid heart action which, as judged by the 
history, resembled atria1 tachycardia. The 
number of attacks was reduced, but the patient 
had headache, chilliness, nausea and a tempera- 
ture of 103.5” F. The symptoms subsided com- 
pletely when antazoline was stopped. One 
month later the drug was resumed, and after 
the patient took the second dose he again had 
nausea, chilliness and a temperature of 103.5” F. 
The white blood cell count was 10,000, with 
16 per cent eosinophils. The symptoms sub- 
sided when the drug was stopped. One addi- 
tional tablet was taken three months later, and 
the patient again had nausea, diarrhea and 
fever (101.5’ F). There was no history of 
asthma or hay fever in this patient. 
Diarrhea occurred in only 5 per cent of the 
patients, but when it occurred it was often 
severe enough to necessitate stopping the drug. 
One case will illustrate this point: 
A 66 year old woman had many ventricular 
premature beats occurring in runs, which con- 
stituted her “attacks.” These were slightly 
reduced by actual count during antazoline 
therapy, and the drug was considered slightly 
effective after a 6 month study period. Mild 
nausea and diarrhea were noted at the onset of 
therapy, but these symptoms were not severe 
enough to stop therapy. By the fifth month 
the patient was having five to six watery stools 
daily. When antazoline was stopped, the 
symptoms disappeared, only to recur when 
antazoline was given again. 
Neurologic Side Ejects: Five patients had 
symptoms referable to the central nervous sys- 
tern. These symptoms were described as the 
“shakes” and consisted of uncontrollable tremor 
that occurred in 1 patient with a dose of 200 
mg. four times a day and disappeared when the 
dose was reduced to 100 mg. four times a day. 
One patient experienced nausea and severe 
paresthesias of all four limbs following 350 mg. 
of anlazoline given intravenously in 3 1 i minute 
injection for successful conversion of \-cntricular 
tachycardia to normal sinus rhythm. .L\nother 
patient, a 61 year old man with many ventricular 
premature beats, became profoundly depressed 
and had a clouded sensorium on 100 mg. of 
antazoline four times a day. These symptoms 
disappeared, and the ventricular premature 
beats were controlled intermittently (result 
coded as ineffective) on a dose of 50 mg. four 
titnes a day. A fourth patient, given 100 mg. 
of antazoline four times a day for frequent ven- 
tricular premature beats, experienced light- 
headedness and muscle spasm of the legs. A 
fifth patient, a 53 year old woman, had many 
atria1 and ventricular premature beats occurring 
in runs following repair of an atria1 septal de- 
fect. She became disoriented when given 200 
mg. of antazoline every six hours. This symp- 
tom cleared after antazoline was stopped for 
two days. 
Skin Eruption: A single patient had a marked 
scaling dermatitis of his hands and scalp after 
receiving 200 mg. of antazoline three times a 
day for four months. These lesions cleared 
after the drug was stopped for two weeks. 
SUMMARY 
Antazoline is a comparatively safe and effec- 
tive antiarrhythmic drug in many situations, 
for both the conversion and prevention of 
arrhythmias. It appeared to be most effective 
in the abolition of ventricular tachycardia, 
possibly helpful in 2 cases of cardiac arrest due 
to ventricular fibrillation and beneficial in the 
prevention of atria1 and ventricular pretnature 
beats. It was useful and deserves further trial 
in the prevention of paroxysmal ventricular 
tachycardia. It was almost ineffective in the 
conversion and prophylaxis of atria1 flutter and 
atria1 fibrillation but appeared to be of value 
in the prevention of paroxysmal atria1 tachy- 
cardia. 
There was a high incidence of mild side 
effects, mostly of the gastrointestinal type, some 
of which were prevented by taking the drug 
with meals or with an antacid preparation. 
No irreversible or serious side actions were en- 
countered, but diarrhea, central nervous system 
symptoms and chills and fever necessitated 
stopping the drug in a small percentage of 
patients. 
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